The Age ·general ·4 hours ago

Why ‘Big Pharma’ isn’t cashing in on the peptide craze

Big pharmaceutical companies are largely avoiding the booming illegal peptide market in Australia as they deem the products unsafe and unprofitable. Novo Nordisk's Ana Svensson stated that popular peptides like BPC-157 and Melanotan II lack the rigorous testing needed for safety and effectiveness. Experts emphasize that many of these peptides are still experimental and do not meet development standards.

Summary by Glance · The Age

Next